No Data
No Data
Shanxi Zhendong Pharmaceutical (300158.SZ) has not yet entered into drug research for cellular immunotherapy for tumors.
Shanxi Zhendong Pharmaceutical (300158.SZ) stated on the Investor Interaction Platform on August 6 that the company has not yet entered into research on drugs for cell immunotherapy of tumors.
Shanxi Zhendong Pharmaceutical (300158.SZ): No production of vitamin raw materials.
On July 1, Gelunhui reported that Shanxi Zhendong Pharmaceutical (300158.SZ) stated on their investor platform that the company held the Fourth Extraordinary General Meeting of Shareholders in September 2, 2021, and approved the Proposal on Selling the Equity of Wholly-owned Subsidiaries. The above-mentioned vitamin products belong to the company, and after the sale of the company, the aforementioned products have no impact on the company's revenue and performance. The company does not produce vitamin raw materials.
Companies Like Shanxi Zhendong PharmaceuticalLtd (SZSE:300158) Are In A Position To Invest In Growth
Zhendong Pharmaceutical (300158.SZ) has repurchased 2.16% of its shares at a total cost of 103 million yuan
Zhitong Finance App News, Zhendong Pharmaceutical (300158.SZ) announced that the company's repurchase has been completed. As of April 30, 2024, the company had repurchased a total of 22.174,900 shares of the company's shares, accounting for 2.16% of the company's total share capital, and the total transaction amount was 103 million yuan (excluding transaction fees).
Investors in Shanxi Zhendong PharmaceuticalLtd (SZSE:300158) From a Year Ago Are Still Down 26%, Even After 9.5% Gain This Past Week
Zhendong Pharmaceutical (300158.SZ) appoints Liu Yongsen as financial director
Zhendong Pharmaceutical (300158.SZ) announced that the company's board of directors recently received the written resignation of Liu Changlu, the company's financial director...
No Data